Millions of women get UTIs each year. An antibiotic 30 years in the making is finally offering hope.
Most UTIs, or urinary tract infections, are anything but subtle. When you've got one, you constantly feel like you need to pee even if you just went, it burns when you go and your urine looks suspiciously cloudy. UTIs are also quite common: More than 50% of women will deal with at least one in their lifetime, and what's worse is that these infections can come back in a matter of months. Treating them has also become trickier. That's because there's a growing number of antibiotic-resistant UTIs, meaning the drugs commonly used to kill the bacteria behind the infection no longer work as well.
'Not only are these infections painful and unpleasant, they are becoming more difficult to treat,' says Dr. Cynthia DeTata, an ob-gyn at Stanford Medicine Children's Health and a clinical assistant professor in maternal-fetal medicine at Stanford Medicine, tells Yahoo. She explains that the most common cause of antibiotic resistance is taking the medications improperly, such as not finishing the entire course of pills as prescribed. 'Partially treating an infection allows rebound growth of bacteria that are now resistant to that antibiotic,' she explains.
Experts say there's an increasing need for new treatments to get UTIs back under control. The challenge? 'The last time a new antibiotic was approved for an uncomplicated UTI was 30 years ago. Our treatments have remained unchanged, while bacteria have continued to evolve,' Dr. Gil Weiss, an ob-gyn at the Association for Women's Health Care and assistant professor of clinical medicine in the department of obstetrics and gynecology at Northwestern Memorial Hospital in Chicago, tells Yahoo.
Now for some good news: There's a new antibiotic on the market called gepotidacin (sold under the brand name Blujepa) that gives doctors a new way to fight pesky UTIs. It's the first new class of antibiotics since the 1990s, and experts say it can help treat UTIs with a lower risk of resistance.
The problem: While there are effective drugs for UTIs, antibiotic-resistant infections are making them harder to treat.
By the numbers: UTIs affect up to 16 million women in the U.S. annually, and for 30 to 44% of them, the infection will come back in a matter of months. Studies suggest that 92% of bacteria behind UTIs are resistant to at least one antibiotic, and nearly 80% don't respond to at least two antibiotics.
The solution: In March 2025, the Food and Drug Administration approved gepotidacin to treat uncomplicated UTIs. (Drugs Pivya and Orlynvah were approved in 2024 to treat UTIs, but they fall into existing antibiotic classes.) 'Gepotidacin is part of a new class of antibiotics called triazaacenaphthylenes,' DeTata says. 'This class is so new that currently, gepotidacin is the only one in it.'
Antibiotics fight bacteria in two main ways: They can kill bacteria (bactericidal) or they can prevent them from multiplying (bacteriostatic), says DeTata. For example, some antibiotics interfere with the formation of bacteria cell walls, causing the wall to burst and killing the bacteria, while others disrupt the synthesis of proteins, which bacteria need to survive. 'Gepotidacin works in an entirely new way by acting on enzymes called topoisomerases, leading to breaks in the DNA strands of bacteria,' DeTata says. 'So gepotidacin is bactericidal, as these breaks in the DNA strands kill the bacteria.'
The drug's main side effects in clinical trials were diarrhea (16% of participants) and nausea (9%), both which are common side effects for antibiotics in general. The research also found that gepotidacin performs just as well as (if not better than) nitrofurantoin, which is a frontline treatment for UTIs.
Added bonus: Gepotidacin 'has the potential to be used for the treatment of gonorrhea, which has also been difficult to treat due to multi-antibiotic resistance,' says DeTata.
For Weiss and many other doctors, having a new treatment option for UTIs is something to celebrate. 'I'm very excited that a new medication has come to market,' he says. 'Any new medication for something so common is a win-win situation.'
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
"Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease." BOSTON, Aug. 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Disease-Modifying Therapies for Alzheimer's Disease: Global Markets" is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030. The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa). This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities. The factors driving the market's growth include: High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies. Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development. Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $235.8 million Market size forecast $13.1 billion Growth rate CAGR of 67.8% for the forecast period of 2025-2030 Segments covered Target Type, Drug Type, Drug Molecule Type, and Region Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa Market drivers • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. Interesting facts: As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules ( There are very few DMTs targeting the moderate to advanced stages of AD. Emerging startups: AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits. TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD. The report addresses the following questions: What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?- The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. Which market segments are covered in the report?- Target type, drug, molecule type, and region. Which target type will be dominant through 2030?- By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. Which molecule type market is growing the fastest?- The large molecule segment is the fastest growing market. What are the key challenges in of the market?- Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs. Market leaders include: ALZHEON INC. ANAVEX LIFE SCIENCES CORP. ANNOVIS BIO INC. BIOGEN BIOVIE INC. EISAI CO. LTD. JOHNSON & JOHNSON LILLY NOVO NORDISK A/S TAURX PHARMACEUTICALS LTD. Related reports: Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential. Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Sign in to access your portfolio
Medscape
5 minutes ago
- Medscape
4 Steps for Keeping a Residency Romance Alive and Thriving
Social Scientist Ruth Diaz went on her first date with a medical resident on his only day off that month. As they wandered through a garden in Portland, Oregon, there was a comfortable familiarity between them, and that feeling soon blossomed into love. Over the course of several months, however, things deteriorated. Missed holidays, communication breakdowns, cold dinners. Their relationship ended in less than a year. Packed schedules, along with physical and mental exhaustion, can make it difficult for residents to maintain any personal life. So when it comes to romantic relationships, attempting to be physically present with partners, let alone emotionally present, can be daunting. While some couples manage to navigate these issues, frequently the demands of residency end up wreaking havoc on romance. And here's a wrinkle: Deteriorating relationships can be a sign of wider struggles. A 2022 study published in the Journal of Neurosurgery found that residents' significant others who reported relationship dissatisfaction were more likely to also report that their resident partners had higher levels of burnout and a lack of work-life balance. 'I didn't look at it like, 'This is your residency's fault,'' Diaz said of her breakup. 'I think it's like how they analyze the Titanic. Part of it was a guy who wanted to retire and went really fast. Part of it was they built the ship badly. And part of it was the weather changes and the bad technology. But I do think among the pressures on our relationship, residency was the iceberg.' So why do some partnerships navigate the iceberg of residency while others hit it head-on? Medscape Medical News asked residents and experts for a four-step relationship treatment plan. Step #1: Adjust Your Relationship With Time The most obvious challenge for residency relationships is a lack of time together. Hiba Hadadin, MD and Yazan Hijazein, MD on their wedding day Hiba Hadadin, MD and Yazan Hijazein, MD, were married on June 15, 2024, in their native Jordan. Four days later, they flew to their new apartment in Louisiana to start residency at LSU Shreveport — she in pediatrics and he in internal medicine. In lieu of a honeymoon, they have since coordinated their few shared days off to travel to nearby states. 'For me, that's basically a honeymoon,' Hadadin said. Hadadin and Hijazein entered residency together through the National Resident Matching Program couples match program. According to a 2021 survey by InCrowd, 58.5% of healthcare professionals in relationships were dating others within healthcare, citing reasons including the ease of meeting people in the field (at least compared with the difficulty of meeting people outside of it) and a shared understanding of the residency schedule. Even if dating fellow residents is easier, it still isn't easy. Hadadin and Hijazein rarely have the same day off. Often, their most romantic dates tend to involve eating lunch together in the hospital cafeteria. Sarah Epstein, LMFT Sarah Epstein, LMFT, a family and couples therapist who often works with healthcare workers, got engaged to her husband during his surgery rotation. 'He successfully negotiated for a 'golden weekend,'' Epstein said, 'or what we normal people call a 'weekend.'' The only constant in residency schedules is change, so Epstein suggests that couples need to adapt continuously. 'The schedule makes getting into a rhythm next to impossible,' Epstein said. 'The moment we settled into one way of being, he switched, and we'd have to adjust again. We had to begin mapping out things on our calendar in advance and being extremely intentional when we had time together. Adjusting became the norm.' Carl G. Streed Jr, MD, and husband, Chad Rubalcaba at Streed's medical school graduation Intentionality and ingenuity go a long way when it comes to navigating erratic residency schedules. Carl G. Streed, Jr, MD, MPH, got engaged to his now-husband Chad Rubalcaba before starting residency in 2014. Without the guarantee of having their anniversaries off, Streed and Rubalcaba created a practice of celebrating 'monthiversaries' whenever Streed had that night off. They're now at almost 200 monthiversaries. Epstein urges couples to set aside even a few minutes of time to check in throughout the week during busy periods. 'Intentionality is at least making it known that 'I see that this is happening, I understand that this is hard on both of us. I miss you too. What can we do? Is there a 5-minute coffee break? Are there sweet texts going back and forth? Is there physical touch happening? Are we going to bed together? How are we going to make this work?'' When asked how their relationships survived or are surviving residency, Hadadin, Streed, and Rubalcaba all said they clung to the impermanence of training. 'Knowing that residency is not forever is mainly what keeps me going,' Hadadin said. 'There are going to be some days that will feel the worst, but there is light at the end of the tunnel, as they say. This is not going to be your lifestyle 5 years from now.' Step #2: Frame Residency Like an Illness Long hours and looming exams can also leave residents emotionally exhausted even when they're off duty. Diaz's dates with her former partner usually involved studying for their respective programs at late-night coffee shops until they couldn't think anymore. 'A lot of our connection couldn't go beyond these basic functions of the screaming visceral demands of our bodies to eat, sleep, drink water, and try to see a scene of nature here and there,' she said. 'He was in a semi-dissociative haze by the time he got out of his shifts.' Streed recalls a similar experience. 'When working in the ICU, I always felt very drained at the end of every shift,' he said. 'I was not as emotionally available in certain situations.' A lack of energy can be even more impactful for dual-healthcare couples. At one point when Hadadin was working night shifts and Hijazein was working during the day, they didn't see each other for 10 days in a row. Now, when they do see each other, they are sometimes too exhausted to truly reconnect. 'I had a month in wards where it was very hectic,' Hadadin said. 'I would just go home and sleep. I didn't have the energy to do anything.' As much as time management, a core component of residency relationships' survival is the management of expectations. 'I would invite anyone dating a resident to frame the program like an illness,' Diaz said. 'It's a chosen illness, but a time of inhuman strain and suffering nonetheless. By seeing it this way, it's easier to recognize that people who have this illness need extra nurturing to cope with the missing function.' Of course, this doesn't mean that nurturing exhausted residents should fall on their nonresident partners. Nor does it mean those partners' needs are less important. Epstein cautions against what she calls 'ranking stress.' 'Everyone is entitled to their experience,' she said. 'My husband is an emergency physician. If my stress was compared to his, mine would be invalidated on a daily basis.' Step #3: Prevent Resentment When Hadadin wakes up on her one day off each week, one of the first things she does is clean the house. But when her residency schedule gets in the way of household chores, her husband picks up the slack, and vice versa. 'We both understand how hectic our schedules can get, so we try to be considerate of each other,' she said. 'I feel so lucky to have a partner who helps out and understands how busy I am.' But when household needs like cooking and cleaning fall on the backburner during residency, these essentials often get neglected completely or to fall on one partner — in heterosexual couples, it's typically the female partner. Sarah Epstein with her husband Speaking from personal experience, Epstein describes this as a 'recipe for resentment.' She found herself taking on a lot more of the housework during her husband's residency, and this remains the case when her husband is in the midst of an especially busy period at work. 'The important thing is us both seeing what's happening, making arrangements for what I'll need when he's less available, and his re-engagement after the busy stretch,' she said. 'He'll do more bedtimes when he's around, or make sure to cook and freeze food before a stretch of overnight shifts. By being aware of which parts of the job can lead to resentment, we can plan and do preventative work.' While balance is important, it's also crucial to recognize that it isn't always going to be a 50/50 split. This is a sentiment Streed and Rubalcaba included in their wedding vows. 'Residency, for me, felt like being selfish, but the nature of residency was that my time was going to be more focused on training,' Streed said. 'Understanding that this is temporary, and we'll work together, is something we put in our vows — this notion of 60/40.' Beyond the practical aspects, domestic duties can sometimes be romantic: Some of Streed's most treasured memories from residency are the times when Rubalcaba would bring him home-cooked meals during long shifts. Step #4: Train for the Future Despite the fact that residency is finite, Epstein points out that practicing physicians' hours often remain long and inconsistent, if to a lesser degree. Instead of seeing residency in a vacuum, she sees it as an intensive preparation period for the ongoing challenges of a life together. 'Some couples fall into this sort of postponement mindset, where the only goal is to get to the other side,' she said. 'But I work with many couples after training where there hasn't been intentionality or good communication, and there's a ton of built-up stuff they now have to deal with. I have never worked with a medical couple that doesn't have some baggage from their time in training.' Diaz also advises residents to acknowledge and process the impacts of residency and 'get therapy' afterward. 'Even if it all seems good on the surface, that doesn't mean that your partner hasn't been absorbing ongoing wounds and not sharing or even staying conscious of them. These wounds will impact your relationship.' Epstein often hears echoes of her own experience when working with couples who are still dealing with the fallout of residency. The good news, she says, is that building empathy, communication skills, and intentional practices can help couples move forward from residency stronger than ever.
Fox News
7 minutes ago
- Fox News
More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs
Print Close By Landon Mion Published August 13, 2025 EXCLUSIVE: More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone, saying it poses "serious risks to women." In a letter obtained by Fox News Digital, 22 attorneys general called on Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drugs Administration head Martin Makary to bring back safeguards for the pills that were scrapped by the Obama and Biden administrations. "Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug's label, while the drug is less than half as effective as claimed. These facts directly contradict the drug's primary marketing message of 'safe' and 'effective,'" the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPA), a Washington, D.C.-based advocacy group. The EPPA report claims the pill presents harm to women, causing 1 in 10 patients to experience a "serious adverse event," including hemorrhage, emergency room visits and ectopic pregnancy. FDA CHIEF HAS 'NO PLANS' FOR ABORTION PILL POLICY CHANGES BUT CONTINUES SAFETY REVIEW The letter, led by Kansas Attorney General Kris Kobach, comes after Kennedy Jr. asked Makary to review the latest data on mifepristone and its safety. "Based on that review, the FDA should consider reinstating safety protocols that it identified as necessary as recently as 2011 in its issuance of a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, but which were removed by the Obama and Biden administrations," the letter reads, adding that the drug should be taken off the market if safeguards cannot be put in place. "Alternatively, in light of the serious risks to women who are presently being prescribed this drug without crucial safeguards, and in the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria," the attorneys general wrote. Sen. Josh Hawley, R-Mo., also sent a letter to Kennedy Jr. last month urging him to take immediate action to reinstate safety guardrails on mifepristone following the secretary's commitment to conducting a safety review of the drug. Makary had previously said that he had no plans to modify policies surrounding mifepristone but that the FDA would act if the data suggested there was a safety issue. Mifepristone, which is taken with another drug called misoprostol to end an early pregnancy, was first approved by the FDA in 2000 after "a thorough and comprehensive review" found it was safe and effective, according to the agency's website, which noted that periodic reviews since its approval have not identified new safety concerns. Last year, the Supreme Court rejected a challenge targeting the drug's availability. The plaintiffs had sought to restrict access to mifepristone across the country, including in Democrat-led states where abortion remains legal. The court did not rule on whether the FDA acted lawfully when it moved during the Obama and Biden administrations to ease the rules for mifepristone's use that had been established during the Clinton administration. Medication abortions made up more than half of all abortions in the U.S. health care system in 2023, according to a study by the Guttmacher Institute. MEDICAL GROUPS URGE FDA, KENNEDY TO REEXAMINE BROAD APPROVAL OF ABORTION DRUGS CLICK HERE TO GET THE FOX NEWS APP "Currently, a woman can obtain a mifepristone abortion by participating in only one telehealth visit with any approved healthcare provider (not necessarily a physician), ordering the drugs through a mail-order pharmacy, and self-administering them," the attorneys general wrote. "And the prescriber is only required to report an adverse event if he or she becomes aware that the patient has died." "The FDA's removal of these crucial safety protocols in 2016 (and in 2023) that only five years before the FDA considered necessary begs the question of whether the removal was motivated by considerations other than the safety of patients … The current FDA's dedication to the health and wellbeing of all Americans is encouraging, as is the much-needed review of mifepristone that Secretary Kennedy has promised," the letter concludes. Print Close URL
